Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

525

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

August 31, 2007

Study Completion Date

September 30, 2008

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

Rifaximin

Trial Locations (67)

11021

Long Island Clinical Research, Great Neck

11042

New York Center for Clinical Research, Lake Success

20815

Chevy Chase Clinical Research, Chevy Chase

20901

Capital Gastroenterology Consultants, PA, Silver Springs

21146

Maryland Clinical Trials, Severna Park

21401

Digestive Disorders Associates, Annapolis

21740

Washington County Hospital, Hagerstown

24541

Internal Medicine Associates, Danville

27262

Bethany Medical Center, High Point

27408

Vital re:Search, Greensboro

27579

University of North Carolina, Chapel Hill

27612

Wake Research Associates, Raleigh

27804

Rocky Mount

27834

Carolina Research, Greenville

28207

Charlotte Gastroenterology & Hepatology, Charlotte

28401

Hanover Medical Specialists, PA, Wilmington

28546

East Carolina Gastroenterology, Jacksonville

28801

Asheville Gastroenterology Associates, Asheville

29203

Columbia Gastroenterology Associates, Columbia

32256

Borland-Groover Clinic, Jacksonville

32720

University Clinical Research, DeLand

32789

Shafran Gastroenterology, Winter Park

33016

Research Consultants Group, Hialeah

33173

Miami Research Associates, Miami

33542

Florida Medical Clinic, Zephyrhills

33765

Clinical Research of West Florida, Clearwater

34684

Advanced Gastroenterology Associates, Palm Harbor

37404

ClinSearch, Chattanooga

37660

Holston Valley Physicians, Kingsport

38305

Regional Research Institute, Jackson

38801

Digestive Health Specialists, PA, Tupelo

39202

Gastrointestinal Associates, PA, Jackson

45219

Consultants for Clinical Research, Cincinnati

45220

Digestive Health Network, Cincinnati

45429

Wells Institute for Health Awareness, Kettering

45440

GI & Liver Diseases Consultants, Dayton

46016

Community Clinical Research Center, Anderson

46237

Indianapolis Gastroenterology Research Foundation, Indianapolis

48047

Henry Ford Hospital, Chesterfield

52807

Gastrointestinal Clinic of Quad Citites, Davenport

53215

Wisconsin Center for Advanced Research, Milwaukee

61107

Rockford Gastroenterology, Rockford

63141

Specialist in Gastroenterology, St Louis

64131

Gastroenterology and Hepatology, Kansas City

65265

Center for Digestive & Liver Diseases, Inc., Mexico

68503

Gastroenterology Specialities, Lincoln

73104

Oklahoma Foundation for Digestive Research, Oklahoma City

73112

Digestive Health Specialists, PA, Oklahoma City

78745

Austin Gastroenterology, Austin

84132

University of Utah School of Medicine, Salt Lake City

84405

Advanced Research Institute, Ogden

85259

Mayo Clinic Scottsdale, Scottsdale

85282

Premeire Pharmaceutical Research, Tempe

90045

West Gastroenterology Medical Group, Los Angeles

90067

Beverly Hills Gastroenterology, Los Angeles

92123

Medical Associates Research Group, San Diego

92618

Lovelace Scientific Resources, Irvine

92801

Advanced Clinical Research Institute, Anaheim

97225

West Hills Gastroenterology Associates, PC, Portland

98004

Northwest Gastroenterology Associates, Bellevue

98052

North Pacific Clinical Research, Redmond

99204

Spokane Digestive Disease Center, Spokane

06606

Gastroenterology Associates of Fairfield County, Bridgeport

06010-0977

Connecticut Gastroenterology Institute, Bristol

06790

Litchfield County Gastroenterology Associates, LLC, Torrington

66160-7350

University of Kansas Medical Center, Kansas City

02184

Coastal Research Associates, Braintree

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT00269412 - Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome | Biotech Hunter | Biotech Hunter